Organized by Li-Huei Tsai of Massachusetts Institute of Technology, Steven M. Paul of Weill Cornell Medical College and Michael Hutton of Lilly UK, the conference will:
Convene with a keynote address by Susan Lindquist of HHMI/Whitehead Institute for Biomedical Research, followed by four days of stimulating plenary and poster sessions;
Explore the latest knowledge in cellular disease mechanisms that involves protein aggregation, cell autophagy, mitochondrial dysfunction, neural circuitry, epigenetics and genome integrity, as they relate to a range of neurodegenerative diseases including Alzheimer’s, amyotrophic lateral sclerosis, fronto-temporal dementia and Parkinson’s
Discuss possibilities for new biomarkers for neurodegenerative disease and new therapeutics, including those based on patient-derived induced neurons and neurons derived from induced pluripotent stem cells;
Identify the most critical outstanding questions in the field of neurogenesis that should be addressed in order to facilitate the development of therapeutic uses of stem cells;
Bring to the table both junior and senior researchers to work together on the common goal of identifying mechanisms underlying neurodegenerative disease.
The meeting will be held jointly with the conference on “Neurogenesis.” Registering for one meeting in a joint pair enables attendance at sessions of the other, pending space availability.